Client Placements

Check out a sampling of results we’ve gotten for our clients.

Endpoints

Ex-GSK CEO Andrew Witty goes biotech, taking a board seat at G1 Read more

Rare Disease Report

CEO of Albireo Pharma Talks PFIC Orphan Drug Read more

FierceBiotech

Medeor gets FDA OK to trial therapy that aims to do away with transplant drugs Read more

CNBC | Mad Money

Cara Therapeutics CEO: Battling Opioids Read more

Harvard Business Review

Pressure Doesn’t Have to Turn into Stress Read more

Life Science Leader

Companies To Watch: Edge Therapeutics Read more

Endpoints

A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD Read more

MIT Technology Review

Startup Aims to Treat Muscular Dystrophy with CRISPR Read more

Investor's Business Daily

Exclusive Q&A: Ionis CEO Sees Watershed 2017 On ‘Rapid’ Drug OKs Read more

STAT

Stop insurers from making end runs around patients with preexisting conditions Read more

FierceBiotech

Edge a step closer to hemorrhage drug approval after FDA fast-track Read more

Xconomy

G1 Therapeutics Hauls in $47M for Lung, Breast Cancer Trials Read more

Philadelphia Business Journal

Malvern biopharm firm licenses drug-delivery technology to Duke Read more

Washington Business Journal

Despite rocky market, Rockville’s Regenxbio on serious growth path Read more

The Boston Globe

Mersana Therapeutics expands partnership with Takeda Read more

CNBC

Biopharmaceutical pros address rising drug prices Read more

FierceBiotech

Cara Therapeutics scores another positive PhII for lead opioid Read more

Bloomberg News

Money Flows Again to Gene-Therapy Drugs Investors Once Shunned Read more

Boston Business Journal

Mersana aims to improve on the world’s third-best selling cancer drug. Here’s how Read more

The Wall Street Journal

Holy Grail: Pain Pills Without the High Read more

The Wall Street Journal | Pharmalot

‘We Had a Bird in the Hand, but…’ NGM Chose Merck: Rieflin Explains Read more

Bloomberg News

Merck’s Research Chief Saved Biotech Deal With Juicy Pitch Read more

Xconomy

Cancer Drug Developer G1 Therapeutics Closes $33M Series B Round Read more

FierceBiotech

Acorda cautiously steps forward with a drug to spur remyelination in MS Read more

The Washington Post

Biotech firm Regenxbio clinches $30M from investors as it plans to pursue clinical trials Read more

USA Today

Scientists close in on non-addictive opioid painkillers Read more

FIERCEBIOTECH

Fledgling Ziarco grabs a $33M transatlantic round for PhII atopic dermatitis drug Read more

Forbes

Trial Shows New Opioid Alternative Could Be Less Addictive Read more

FIERCEBIOTECH

Boehringer, Vitae survive first clinical challenge in a crowded Alzheimer’s race Read more

FierceBiotech

After a string of gene therapy licensing deals, ReGenX says it’s time to shine Read more

Fox Business

Sarepta Therapeutics CEO on efforts to treat Ebola Read more

CNBC

When unapproved drugs are the only hope Read more